Last reviewed · How we verify
Zixoryn (FLUMECINOL)
Zixoryn (generic name: FLUMECINOL) is a drug. It is currently in Phase 2 development.
Zixoryn works by interacting with specific biological pathways, but the exact mechanism is unknown.
Zixoryn (FLUMECINOL) is a small molecule drug with unknown target and drug class. Its commercial status is unclear, and it has not been approved by the FDA for any indications. As a small molecule, it is likely to work by interacting with specific biological pathways, but the exact mechanism is unknown. Further research is needed to determine its efficacy and safety profile. Its development and ownership history are also unclear.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | FLUMECINOL |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | Phase 2 |
Mechanism of action
Imagine your body's cells are like a city with many different roads and intersections. Zixoryn is like a traffic cop that tries to direct the flow of traffic, but we don't know which roads it's trying to control or how it's doing it. This is a simplified way of understanding how Zixoryn might work, but the actual details are much more complex.
Approved indications
Common side effects
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Zixoryn CI brief — competitive landscape report
- Zixoryn updates RSS · CI watch RSS
Frequently asked questions about Zixoryn
What is Zixoryn?
How does Zixoryn work?
What is the generic name of Zixoryn?
What development phase is Zixoryn in?
Related
- Therapeutic area: All drugs in Other
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing